Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 15
Submit an article Journal homepage
84
Views
3
CrossRef citations to date
0
Altmetric
Drug Evaluation

Intravenous alteplase for acute ischaemic stroke

Vincent Larrue Service de neurologie vasculaire, Hôpital Rangueil, 1 avenue Jean Poulhès, 31059 Toulouse, France. [email protected]
Pages 2699-2709 | Published online: 30 Nov 2005

Bibliography

  • CORNU C, BOUTITIE F, CANDELISE L et al.: Streptokinase in acute ischemic stroke: an individual patient data meta-analysis. the thrombolysis in acute stroke pooling project. Stroke (2000) 31(7):1555–1560.
  • HALEY EC JR, LYDEN PD, JOHNSTON KC et al.: A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke (2005) 36(3):607–612.
  • HACKE W, ALBERS G, AL-RAWI Yet al: The desmoteplase in acute ischemic stroke trial (DIAS): a Phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke (2005) 36(1):66–73.
  • ••Patients included in this study were selected for late thrombolysis using multimodal magnetic resonance imaging.
  • ASSENT INVESTIGATORS: Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet (1999) 354(9180):716–722.
  • BELL WR JR: Defibrinogenating enzymes. Drugs (1997) 54\(Suppl. 3):18–30.
  • SHERMAN DG, ATKINSON RP, CHIPPENDALE T et al.: Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA (2000) 283(18):2395–2403.
  • LIU M, COUNSELL C, ZHAO KL: Fibrinogen-depleting agents for acute ischemic stroke. Cochrane Database Syst. Rev. (2003) 3:CD000091.
  • Reassessment of defibrase in treatment of cerebral infarction. Chinese J. NeuroL (2000) 33(5):263–267.
  • ORGOGOZO JM, VERSTRAETE M, KAY R et al.: Outcomes of ancrod in acute ischemic stroke. JAMA (2000) 284(15):1926–1927.
  • ABEST INVESTIGATORS: Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized Phase II trial. Stroke (2005) 36(4):880–890.
  • FURLAN A, HIGASHIDA R, WECHSLER L et al.: Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA (1999) 282(21):2003–2011.
  • ••The only randomised, controlled trial ofintra-arterial thrombolysis.
  • SCHUMACHER HC, GUPTA R, HIGASHIDA R et al.: Advances in revascularization for acute ischemic stroke treatment. Expert Rev. Neurotherapeutics (2005) 5(2):189–201.
  • SMITH WS, SUNG G, STARKMAN S et al.: Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI. Stroke (2005) 36(7):1432–1438
  • BACHMANN F: The plasminogen-plasmin enzyme system. Hemostasis and thrombosis: basic principles and clinical practice, 3rd edn. Colman RW, Hirsh J, Marder VJ, and Salzman EW (Eds), J.B. Lippincot Company, Philadelphia (1994):1592–1622.
  • BELL WR: Present-day thrombolytic therapy: therapeutic agents. Pharmacokinetics and pharmacodynamics. Rev. Cardiovasc. Med. (2002) 3\(Suppl. 2):34–44.
  • MUELLER HS, RAO AK, FORMAN SA: Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. J. Am. Coll. Cardiol. (1987) 10(3):479–490.
  • TOPOL EJ, MORRIS DC, SMALLING RW et al.: A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction. J. Am. Coll. CardioL (1987) 9(0:1205–1213.
  • HACKE W, KASTE M, FIESCHI C et al.: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) JAMA (1995) 274(13):1017–1025.
  • BROTT TG, HALEY EC JR, LEVY DE et al.: Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke (1992) 23:632–640.
  • THE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE RT-PA STROKE STUDY GROUP: Tissue plasminogen activator for acute ischemic stroke. N EngL J. Med. (1995) 333:1581–1587.
  • ••The pivotal study demonstratingthe efficacy of intravenous alteplase in acute ischaemic stroke within 3 h of symptom onset.
  • CLARK WM, ALBERS GW, MADDEN KP et al.: The rtPA (alteplase) 0- to 6-hour acute stroke trial, Part A (A0276g). Results of a double-blind, placebo-controlled, multicenter study. Stroke (2000) 31:811–816.
  • ALBERS GW, CLARK WM, MADDEN KP et al.: ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. Stroke (2002) 33(2):493–495.
  • CLARK WM, WISSMAN S, ALBERS GW et al.: Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA (1999) 282(21):2019–2026.
  • HACKE W, KASTE M, FIESCHI C et al.: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet (1998) 352(9136):1245–1251.
  • WARDLAW J, ZOPPO G, YAMAGUCHI T et al.: Thrombolysis for acute ischemic stroke. Cochrane Database Syst. Rev. (2003) 3:CD000213.
  • HACKE W, DONNAN G, FIESCHI C et al.: Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet (2004) 363(9411):768–774.
  • ••This meta-analysis shows that the efficacyof alteplase is time dependent.
  • DEL ZOPPO GJ, POECK K, PESSIN MS et al.: Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann. NeuroL (1992) 32:78–86.
  • ••An angiographic study documenting theefficacy of intravenous rtPA according to the site of brain artery occlusion.
  • ALEXANDROV AV, GROTTA JC: Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology (2002) 59:862–867.
  • HEO JH, LEE KY, KIM SH et al.: Immediate reocclusion following a successful thrombolysis in acute stroke: a pilot study. Neurology (2003) 60:1684–1687.
  • CINTAS P, NGUYEN F, BONEU B et aL:Enhancement of enzymatic fibrinolysis with 2-MHz ultrasound and microbubbles. Thromb. Haemost. (2004) 2(7):1163–1166.
  • EVERBACH EC, FRANCIS CW: Cavitational mechanisms in ultrasound-accelerated thrombolysis at 1 MHz. Ultrasound Med. Biol. (2000) 26:1153–1160.
  • EGGERS J, KOCH B, MEYER K et al.: Effect of ultrasound on thrombolysis of middle cerebral artery occlusion. Ann. Neurol. (2003) 53:797–780.
  • ••The first randomised controlled trialsuggesting that intravenous thrombolysis with alteplase can be enhanced by transcranial application of ultrasound.
  • ALEXANDROV AV, MOLINA A, GROTTAJC et al.: Ultrasound-enhanced thrombolysis for acute ischemic stroke. N EngL J. Med. (2004) 351:2170–2178.
  • THE IMS STUDY INVESTIGATORS: Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the interventional management of stroke study. Stroke (2004) 35(4):904–911.
  • ••A study that demonstrates thefeasibility of combined intravenous and intra-arterial thrombolysis.
  • EISENBERG PR, SOBEL BE, JAFFE AS: Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J. Am. Coll. Cardiol (1992) 19:1065–1069.
  • DE LUCA G, SURYAPRANATA H, STONE G et al.: Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA (2005) 293(14):1759–1765.
  • MORRIS DC, SILVER B, MITSIAS P et al.: Treatment of acute ischemic stroke with recombinant tissue plasminogen activator and abciximab. Acad. Emerg Med. (2003) 10(12):1396–1399.
  • STRAUB S, JUNGHANS U, JOVANOVIC E et al.: Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion. Stroke (2004) 35(3):705–709.
  • SEITZ RJ, MEISEL S, MOLL M et al.: The effect of combined thrombolysis with rtPA and tirofiban on ischemic brain lesions. Neurology (2004) 62(11):2110–2112.
  • SEITZ RJ, HAIVIZAWI M, JUNGHANS U et al.: Thrombolysis with rtPA and tirofiban in acute stroke: a pilot study. Stroke (2003) 34(8):1932–1935.
  • LARRUE V: Complications of thrombolysis. In: Thrombolytic and antithrombotic therapy for stroke. Bogousslavsky J, Hacke W (Eds), Taylor & Francis, London (2004).
  • MOLINA CA, ALVAREZ-SABIN J, MONTANER J et al.: Thrombolysis-related hemorrhagic infarction: a marker of early reperfitsion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke (2002) 33(6):1551–1556.
  • LARRUE V VON KUMMER R, MULLER A, BLUHMI E: Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke (2001) 32(2):438–441.
  • ••An analysis of risk factors for intracerebralhaemorrhage after intravenous alteplase for acute ischaemic stroke.
  • TANNE D, KASNER SE, DEMCHUK AM et al.: Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation (2002) 105(14):1679–1685.
  • TONG D, ADAMI A, MOSELEY M et a/. : Relationship between apparent diffusion coefficient and subsequent hemorrhagic transformation following acute ischemic stroke. Stroke (2000) 31:2378–2384.
  • SELIM M, FINK JN, KUMAR S et al.: Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognosticvalue of initial apparent diffusion coefficient and diffusion-weighted lesion volume. Stroke (2002) 33:2047–2052.
  • YEPES M, SANDKVIST M, MOORE EG et al.: Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. Clin. Invest. (2003) 112(10):1533–1540.
  • WANG X, LEE SR, ARAI K et aL: Lipoprotein receptor mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat. Med. (2003) 9(10):1313–1317.
  • BENCHENANE K, BEREZOWSKI CARINE A et al.: Tissue-type plasminogen activator crosse the intact blood brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Stroke (2005) 111(17):2241–2249.
  • KAUR J, ZHAO Z, KLEIN GM et al.: The neurotoxicity of tissue plasminogen activator? J. Cereb. Blood Flow Metab. (2004) 24(9):945–963.
  • ALBERS GW, BATES VE, CLARK WM et al.: Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA (2000) 283(9):1145–1150.
  • HILL MD, BUCHAN AM, CASES INVESTIGATORS: Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ (2005) 172(10):1307–1312.
  • ••A well conducted postmarketing study ofalteplase in acute ischaemic stroke.
  • GRAHAM G: Tissue plasminogen activator for acute ischemic stroke in clinical practice. A meta-analysis of safety data. Stroke (2003) 34(12):2847–2850.
  • HEUSCHMANN PU, BERGER K, MISSELWITZ B et al.: Frequency of thrombolytic therapy in patients with acute ischemioc stroke and the risk of in-hospital mortality: the German Stroke Registers Group. Stroke (2003) 34(5):1106–1113.
  • SIMON JE, SANDLER DL, WARWICK PEXMAN JH et al.: Is intravenous recombinant tissue plasminogen activator (rt-PA) safe for use in patients over 80 years old with acute ischaemic stroke? The Calgary experience. Age Ageing (2004) 33(2):143–149.
  • KATZAN IL, HAMMER M, FURLAN A et al.: Quality improvement and tissuetype plasminogen activator for acute ischemic stroke: a Cleveland update. Stroke (2003) 34(3):799–800.
  • KIDWELL C, ALGER J, SAVER J: Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging. Stroke (2003) 34(11):2729–2735.
  • VIGUIER A, PETIT R, RIGAL M et aL: Continuous monitoring of middle cerebral artery recanalization with transcranial color-coded sonography and levovist. j Thromb. Thrombolysis (2005) 19(1):55–59. Websites

Websites

  • http://www.strokecenter.org/trials/ TrialDetail.aspx?tid=568 Abciximab in Emergent Stroke Treatment Trial-II. Accessed 4 October, 2005.
  • http://www.strokecenter.org/trials/ TrialDetail.aspx?tid=574 Microbubbles and Ultrasound in Stroke Trial. Accessed 4 October, 2005.
  • http://www.strokecenter.org/trials/ TrialDetail.aspx?tid=487 Interventional Management of Stroke Study (IMS II). Accessed 4 October, 2005.
  • http://www.strokecenter.org/trials/ TrialDetail.aspx?tid=478 Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke trial. Accessed 4 October, 2005.
  • http://www.acutestroke.org Safe Implementation of Thrombolysi in Stroke Monitoring Study. Accessed 18 November, 2005.
  • http://www.acutestroke.org/ index.php?module=ContentExpress8cfunc= display8cceid=508thid=208cbtitle=SITS°/02 ORegister8cmeid=4 Safe Implementation of Thrombolysis in Stroke International Thrombolysis register. Accessed 4 October, 2005.
  • http://www.strokecenter.org/trials/ TrialDetail.aspx?tid=475 European Acute Stroke Study III. Accessed 18 November, 2005.
  • http://www.ist3.com Third International Stroke Trial. Accessed 4 October, 2005
  • http://www.astn.org.au/epithet EchoPlanar Imaging Thrombolysis Evaluation Trial. Accessed 4 October, 2005.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.